adenoid cystic carcinoma of the head and neck
Conditions
Interventions
Intervention group:Radiotherapy combined with anlotinib
Sponsors
Eye, Ear, Nose & Throat Hospital of Fudan University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Aged > 18 years old and 2000/mm^3, platelet count > 100,000/mm^3 9. Liver and renal function examinations before treatment meet the following criteria: bilirubin 60 ml/min 10. Signed informed consent form before the start of the study
Exclusion criteria
Exclusion criteria: 1. Head and neck malignant tumors with a pathological type other than adenoid cystic carcinoma 2. Cases not jointly discussed with head and neck surgeons 3. Early-stage head and neck adenoid cystic carcinoma (ACC) or head and neck ACC that can be completely resected by surgery 4. Evidence or suspicious evidence of distant metastasis found in clinical examination or imaging examination 5. Not receiving treatment for the first time (i.e., prior anti-tumor treatment history) 6. History of malignant tumors or concurrent multiple primary tumors (except basal cell carcinoma of the skin) 7. Positive pregnancy test result in women of childbearing age 8. Concurrent diseases or conditions that affect the patient’s normal enrollment or safety during the study 9. Active mental disorders or other psychological illnesses that affect the patient’s ability to sign the informed consent form and understand the study 10. Uncontrolled active infection
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Local Control Rate;Distant Disease-Free Survival rate;Overall survival rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Eyeball retention rate; | — |
Countries
China
Contacts
Public ContactShengzi Wang, Xiaoshen Wang, Li Wang
Eye, Ear, Nose & Throat Hospital of Fudan
Outcome results
None listed